Recombinant Modified Vaccinia Virus Ankara (MVA) Foot and Mouth Disease Virus (FMDV) Vaccine

Abstract

The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject.

We claim: 
     
         1 . A vaccine that elicits a protective immune response to FMDV when administered to cattle and that comprises:
 (a) a recombinant MVA comprising:
 (i) a first transcriptional unit that comprises a nucleotide sequence encoding the foot-and-mouth disease virus (FMDV) P1 region operably liked to a promoter; and 
 (ii) a second transcriptional unit that comprises a nucleotide sequence encoding FMDC 3C protease, wherein the 3C protease comprises the mutation C142T; and 
   (b) a pharmaceutical or veterinary acceptable carrier, excipient or vehicle;   
       wherein said protective immune response prevents the development of FMDV-caused lesions in said cattle.